UMR CNRS 8612
Institut Galien Paris-Sud

Home > Introduction > Its scientific strategy

Its scientific strategy



Nano and micromedicines have shown great potential for significantly improving the treatment of serious diseases as well as those resistant to existing treatments.

Indeed, no medicine can exert a therapeutic activity if the active drug it contains is not able to cross the biological barriers that separate the administration site from the site of action.

In this context, many active ingredients exhibit physicochemical characteristics (hydrophilicity, molecular weight etc ... ) that hinder their passage of biological barriers and / or their intracellular trafficking.

Others face barriers resulting from enzymatic degradation and rapid metabolism. Many others are characterized by a very low selectivity, so that their therapeutic activity is obtained at the cost of high toxicity.

In addition, products derived from biotechnology are today accessible in large quantities and are undoubtedly the basis for future drugs.

However their physicochemical characteristics and biomimetic effects render them very difficult to administer. They are, indeed, always poorly absorbed (at the cellular and tissue level) and often rapidly degraded and metabolized, thereby limiting the development of these molecules as drugs.

The main objective of UMR CNRS 8612 is to solve these problems by developing new and original systems of administration and drug carriers (nano- and microtechnologies), or contrast agents or nanotechnology for the diagnosis in vitro.

The development of such systems benefits first from the contribution of physical chemistry to better design these delivery systems and to characterize them.

This approach should also lead to a deeper understanding of the technologies used in the formulation process and allow new concepts to be developed.

Finally, as stated above, cellular and molecular biology is essential to better understand cellular distribution mechanisms, to develop biological models for the evaluation of new carriers and also to identify new biological targets for drug targeting.

Based on this strategy, the Institute is structured around two large groups (i) The Physical Chemists represented by four teams one of which focuses on analytical chemistry (ii) The Pharmaceutical Technologists composed of three teams which are at the interface of chemistry and biology. These groups benefit from the technical support of five facilities: (i) Cell Culture facility, (ii) Radioactivity facility, (iii) Prototype workshop, (iv) Analytical Service, (v) Molecular interaction service and (vi) Administrative services. The laboratory is a partner in two Labex consortia (LERMIT and NANOSACLAY)..

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accueil Imprimer Contact Plan du site Credits